IDYA
Price
$24.50
Change
-$0.33 (-1.33%)
Updated
Jul 25 closing price
Capitalization
2.15B
17 days until earnings call
IONS
Price
$42.15
Change
-$0.00 (-0.00%)
Updated
Jul 25 closing price
Capitalization
6.72B
4 days until earnings call
Interact to see
Advertisement

IDYA vs IONS

Header iconIDYA vs IONS Comparison
Open Charts IDYA vs IONSBanner chart's image
IDEAYA Biosciences
Price$24.50
Change-$0.33 (-1.33%)
Volume$883.55K
Capitalization2.15B
Ionis Pharmaceuticals
Price$42.15
Change-$0.00 (-0.00%)
Volume$374
Capitalization6.72B
IDYA vs IONS Comparison Chart in %
Loading...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IONS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IDYA vs. IONS commentary
Jul 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a StrongBuy and IONS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 26, 2025
Stock price -- (IDYA: $24.50 vs. IONS: $42.24)
Brand notoriety: IDYA and IONS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 81% vs. IONS: 51%
Market capitalization -- IDYA: $2.15B vs. IONS: $6.72B
IDYA [@Biotechnology] is valued at $2.15B. IONS’s [@Biotechnology] market capitalization is $6.72B. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 0 FA rating(s) are green whileIONS’s FA Score has 0 green FA rating(s).

  • IDYA’s FA Score: 0 green, 5 red.
  • IONS’s FA Score: 0 green, 5 red.
According to our system of comparison, IDYA is a better buy in the long-term than IONS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 4 TA indicator(s) are bullish while IONS’s TA Score has 4 bullish TA indicator(s).

  • IDYA’s TA Score: 4 bullish, 4 bearish.
  • IONS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both IDYA and IONS are a good buy in the short-term.

Price Growth

IDYA (@Biotechnology) experienced а +13.48% price change this week, while IONS (@Biotechnology) price change was +1.16% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.58%. For the same industry, the average monthly price growth was +17.35%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

IDYA is expected to report earnings on Nov 11, 2025.

IONS is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+7.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IONS($6.72B) has a higher market cap than IDYA($2.15B). IONS YTD gains are higher at: 20.838 vs. IDYA (-4.669). IDYA (-356.46M) and IONS (-357.21M) have comparable annual earnings (EBITDA) . IONS has more cash in the bank: 2.15B vs. IDYA (693M). IDYA has less debt than IONS: IDYA (26M) vs IONS (1.41B). IONS has higher revenues than IDYA: IONS (717M) vs IDYA (7M).
IDYAIONSIDYA / IONS
Capitalization2.15B6.72B32%
EBITDA-356.46M-357.21M100%
Gain YTD-4.66920.838-22%
P/E RatioN/AN/A-
Revenue7M717M1%
Total Cash693M2.15B32%
Total Debt26M1.41B2%
FUNDAMENTALS RATINGS
IDYA vs IONS: Fundamental Ratings
IDYA
IONS
OUTLOOK RATING
1..100
1369
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
96
Overvalued
PROFIT vs RISK RATING
1..100
72100
SMR RATING
1..100
9498
PRICE GROWTH RATING
1..100
4844
P/E GROWTH RATING
1..100
10069
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (63) in the null industry is somewhat better than the same rating for IONS (96) in the Biotechnology industry. This means that IDYA’s stock grew somewhat faster than IONS’s over the last 12 months.

IDYA's Profit vs Risk Rating (72) in the null industry is in the same range as IONS (100) in the Biotechnology industry. This means that IDYA’s stock grew similarly to IONS’s over the last 12 months.

IDYA's SMR Rating (94) in the null industry is in the same range as IONS (98) in the Biotechnology industry. This means that IDYA’s stock grew similarly to IONS’s over the last 12 months.

IONS's Price Growth Rating (44) in the Biotechnology industry is in the same range as IDYA (48) in the null industry. This means that IONS’s stock grew similarly to IDYA’s over the last 12 months.

IONS's P/E Growth Rating (69) in the Biotechnology industry is in the same range as IDYA (100) in the null industry. This means that IONS’s stock grew similarly to IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IDYAIONS
RSI
ODDS (%)
Bearish Trend 1 day ago
54%
Bearish Trend 1 day ago
68%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
62%
Momentum
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 1 day ago
68%
MACD
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
77%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
68%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
70%
Advances
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 4 days ago
63%
Declines
ODDS (%)
Bearish Trend 9 days ago
77%
Bearish Trend 9 days ago
69%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
76%
Aroon
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 1 day ago
67%
View a ticker or compare two or three
Interact to see
Advertisement
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IONS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EPGCX15.29N/A
N/A
Fidelity Advisor Equity Growth C
PINDX20.72N/A
N/A
Victory Pioneer Disciplined Growth A
NMULX11.21N/A
N/A
Neuberger Berman Multi-Cap Opp I
BTSMX25.16N/A
N/A
Boston Trust SMID Cap
QMGYX12.95N/A
N/A
Invesco Advantage International Y